STOCKHOLDERS AGREEMENT
Exhibit
2
AGREEMENT, dated as of December 3, 2002 among Syngenta Participations AG,
a corporation organized under the laws of Switzerland ("SPARTAG"), Xxxxxx
Xxxx Research Institute, a Delaware corporation ("TMRI", and together
with SPARTAG, the "Syngenta Parties"), and each of the stockholders of
Diversa Corporation, a Delaware corporation (the "Company") set forth
under the caption "Diversa Stockholders" on the signature pages hereto (each, a
"Stockholder", and collectively, the "Stockholders").
WHEREAS, in order to induce the Syngenta Parties to enter into the
Transaction Agreement, dated as of the date hereof (the "Transaction
Agreement"), with the Company and the other Transaction Documents, the
Syngenta Parties have requested each Stockholder, and each Stockholder has
agreed, to enter into this Agreement with respect to all shares of common stock,
par value $0.001 per share, of the Company that such Stockholder beneficially
owns (the "Subject Shares"). Capitalized terms used but not otherwise
defined herein have the meanings assigned to them in the Transaction Agreement.
WHEREAS, pursuant to the Transaction Agreement, the Company has agreed to
issue (the "Issuance") to the Syngenta Parties (or their designated
Affiliates) the Shares and the Warrant as well as the Warrant Shares issuable
upon exercise of the Warrant.
NOW, THEREFORE, the parties hereto agree as follows:
ARTICLE 1
GRANT OF PROXY; VOTING
AGREEMENT
Section 1.01. Voting Agreement. Each of the Stockholders hereby
agrees to vote all Subject Shares that such Stockholder is entitled to vote at
the time of any vote to approve the Issuance at any meeting of the stockholders
of the Company, and at any adjournment thereof, at which the Issuance is
submitted for the consideration and vote of the stockholders of the Company (the
"Diversa Stockholders Meeting"). Each of the Stockholders hereby agrees
that it will not vote any Subject Shares in favor of the approval of any action
which would reasonably be expected to prevent, delay, postpone, impede,
interfere with, frustrate the purposes of, or discourage the consummation of,
the transactions contemplated by the Transaction Agreement.
Section 1.02. Irrevocable Proxy. Each of the Stockholders hereby
revokes any and all previous proxies granted with respect to such Stockholder's
Subject Shares. By entering into this Agreement, each of the Stockholders hereby
grants a proxy appointing SPARTAG as such Stockholder's attorney-in-fact and
proxy, with full power of
substitution, for and in such Stockholder's name, to vote for or consent to (by
executing a written consent with respect thereto) the Issuance and any related
matter coming up at the Diversa Stockholders Meeting (including without
limitation to vote on any adjournment of such meeting). Subject to Section 1.01,
the Stockholders shall be entitled to vote the Subject Shares on all other
matters. The proxy granted by each of the Stockholders pursuant to this Article
1 is irrevocable during the term of this Agreement and is granted in
consideration of the Syngenta Parties entering into this Agreement and the
Transaction Agreement and incurring certain related fees and expenses. The proxy
granted by each of the Stockholders shall be revoked upon termination of this
Agreement in accordance with its terms.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES
OF THE STOCKHOLDERS
Each of the Stockholders, severally as to itself, himself or herself,
represents and warrants to the Syngenta Parties that:
Section 2.01. Corporation Authorization. (a) If such Stockholder
is not an individual, the execution, delivery and performance by such
Stockholder of this Agreement and the consummation by such Stockholder of the
transactions contemplated hereby are within the corporate or similar powers of
such Stockholder and have been duly authorized by all necessary corporate or
similar action. This Agreement constitutes a valid and binding Agreement of such
Stockholder.
(b) If such Stockholder is a married individual and the Subject Shares
set forth on Exhibit A hereto opposite such Stockholder's name constitute
community property under applicable laws, this Agreement has been duly
authorized, executed and delivered by, and constitutes the valid and binding
agreement of, such Stockholder's spouse. If this Agreement is being executed in
a representative or fiduciary capacity, the Person signing this Agreement has
full power and authority to enter into and perform this Agreement.
Section 2.02. Non-Contravention. The execution, delivery and
performance by such Stockholder of this Agreement and the consummation of the
transactions contemplated hereby do not and will not (i) if such Stockholder is
not an individual, violate the certificate of incorporation or bylaws (or other
organizational documents) of such Stockholder, (ii) violate any applicable law,
rule, regulation, judgment, injunction, order or decree, (iii) require any
consent or other action by any Person under, constitute a default under any
provision of any agreement or other instrument binding on such Stockholder or
(iv) result in the imposition of any Lien (other than (A) the agreement by such
Stockholder to vote its Subject Shares for the Issuance and (B) the irrevocable
proxy granted pursuant to Section 1.02) on any Subject Shares of such
Stockholder.
2
Section 2.03. Ownership of Subject Shares. Such Stockholder is the
record and beneficial owner of the Subject Shares set forth beside its, his or
her name on Exhibit A hereto, free and clear of any restriction on the right to
vote such Subject Shares. None of such Subject Shares is subject to any voting
trust or other agreement or arrangement with respect to the voting of such
Subject Shares.
Section 2.04. Total Subject Shares. Except for the Subject Shares
set forth beside its, his or her name on Exhibit A hereto, such Stockholder does
not beneficially own any shares of capital stock or voting securities of the
Company.
Section 2.05. Finder's Fees. No Syngenta Party (or its Affiliates)
is or will be responsible to pay any fee or commission to any investment banker,
broker, finder or other intermediary in respect of this Agreement based upon any
arrangement or agreement made by or on behalf of such Stockholder.
Section 2.06. Reliance by the Syngenta Parties. Such Stockholder
understands and acknowledges that the Syngenta Parties are entering into the
Transaction Agreement and the other Transaction Documents in reliance upon such
Stockholder's execution, delivery and performance of this Agreement.
ARTICLE 3
COVENANTS OF THE STOCKHOLDERS
Each of the Stockholders hereby, severally as to itself, himself or
herself, covenants and agrees that:
Section 3.01. No Interference; Transfers. Except pursuant to the
terms of this Agreement, such Stockholder shall not, without the prior written
consent of the Syngenta Parties, directly or indirectly, (i) grant any proxies
or enter into any voting trust or other agreement or arrangement with respect to
the voting of any Subject Shares, (ii) take any action that would or is
reasonably likely to (A) make any representation or warranty contained herein
untrue or incorrect in any material respect or (B) have the effect in any
material respect of preventing such Stockholder from performing its obligations
under this Agreement, or (iii) sell, assign, transfer, encumber or otherwise
dispose of, or enter into any contract, option or other arrangement or
understanding (each, a "Transfer") with respect to the direct or indirect
sale, assignment, transfer, encumbrance or other disposition of, any Subject
Shares during the term of this Agreement, unless the transferee in such Transfer
agrees in writing to be bound by the terms of this Agreement and executes a
counterpart to this Agreement making such transferee bound hereby.
3
ARTICLE 4
MISCELLANEOUS
Section 4.01. Further Assurances. The parties hereto agree that
the terms of this Agreement will apply to any written consent in lieu of the
Diversa Stockholders Meeting. Each Stockholder will execute and deliver, or
cause to be executed and delivered, (i) any further documents and instruments
related to, or required to effect the provisions of this Agreement in connection
with, any such written consent in lieu of the Diversa Stockholders Meeting and
(B) any form of proxy required at the Diversa Stockholders Meeting to effect the
provisions of Section 1.02.
Section 4.02. Amendments; Termination. Any provision of this
Agreement may be amended or waived if, but only if, such amendment or waiver is
in writing and is signed, in the case of an amendment, by each party to this
Agreement or in the case of a waiver, by the party against whom the waiver is to
be effective. This Agreement shall terminate upon the earlier of (i) the
completion of the Closing and (ii) the termination of the Transaction Agreement
in accordance with its terms; provided that this Article 4 shall survive
any such termination.
Section 4.03. Expenses. All costs and expenses incurred in
connection with this Agreement shall be paid by the party incurring such cost or
expense.
Section 4.04. Successors and Assigns. The provisions of this
Agreement shall be binding upon and inure to the benefit of the parties hereto
and their respective successors and permitted assigns.
Section 4.05. Governing Law. This Agreement shall be construed in
accordance with and governed by the laws of the State of Delaware (without
regard to conflicts of laws principles).
Section 4.06. Jurisdiction. Except as otherwise expressly provided
in this Agreement, the parties hereto agree that any suit, action or proceeding
seeking to enforce any provision of, or based on any matter arising out of or in
connection with, this Agreement or the transactions contemplated hereby shall be
brought in the Chancery Court of the State of Delaware (or other appropriate
state court in the State of Delaware) or the Federal courts located in the State
of Delaware, so long as one of such courts shall have subject matter
jurisdiction over such suit, action or proceeding, and that any cause of action
arising out of this Agreement shall be deemed to have arisen from a transaction
of business in the State of Delaware, and each of the parties hereby irrevocably
consents to the jurisdiction of such courts (and of the appropriate appellate
courts therefrom) in any such suit, action or proceeding and irrevocably waives,
to the fullest extent permitted by law, any objection that it may now or
hereafter have to the laying of the venue of any such suit, action or proceeding
in any such court or that any such suit, action or proceeding which is brought
in any such court has been brought in an
4
inconvenient forum.
Process in any such suit, action or proceeding may be served on any party
anywhere in the world, whether within or without the jurisdiction of any such
court.
Section 4.07. Waiver of Jury Trial. EACH OF THE PARTIES HERETO
HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY.
Section 4.08. Counterparts; Effectiveness. This Agreement may be
signed in any number of counterparts, each of which shall be an original, with
the same effect as if the signatures thereto and hereto were upon the same
instrument.
Section 4.09. Severability. If any term, provision or covenant of
this Agreement is held by a court of competent jurisdiction or other authority
to be invalid, void or unenforceable, the remainder of the terms, provisions and
covenants of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated.
Section 4.10. Specific Performance. The parties hereto agree that
irreparable damage would occur in the event any provision of this Agreement is
not performed in accordance with the terms hereof and that the parties shall be
entitled to specific performance of the terms hereof in addition to any other
remedy to which they are entitled at law or in equity.
5
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.
SYNGENTA PARTICIPATIONS
AG | ||||
By: |
/s/ Xxxxxx X.
Xxxxxx
| |||
Name: |
Xxxxxx X.
Xxxxxx | |||
Title: |
Head: Mergers &
Acquisitions, Ventures and Licensing | |||
By: |
/s/ Xxxxxx X.
Xxxxxxxx
| |||
Name: |
Xxxxxx X.
Xxxxxxxx | |||
Title: |
Head of Global
Intellectual Property | |||
XXXXXX XXXX RESEARCH
INSTITUTE | ||||
By: |
/s/ Xxxxxx X.
Xxxxxx
| |||
Name: |
Xxxxxx X.
Xxxxxx | |||
Title: |
Attorney in
fact |
(additional signature pages follow)
Diversa
Stockholders
HEALTHCARE VENTURES III,
L.P. | ||||
By: |
||||
Its: |
General
Partner | |||
By: |
/s/ Xxxxxxx
Xxxxxxxxx | |||
| ||||
Name: |
Xxxxxxx
Xxxxxxxxx | |||
Title: |
Administrative Partner of
HealthCare
Partners III,
L.P. | |||
The General Partner of
HealthCare
Ventures, III,
L.P. |
HEALTHCARE VENTURES IV,
L.P. | ||||
By: |
||||
Its: |
General
Partner | |||
By: |
/s/ Xxxxxxx
Xxxxxxxxx | |||
| ||||
Name: |
Xxxxxxx
Xxxxxxxxx | |||
Title: |
Administrative Partner of
HealthCare
Partners IV,
L.P. | |||
The General Partner of
HealthCare
Ventures, IV,
L.P. |
HEALTHCARE VENTURES V,
L.P. | ||||
By: |
||||
Its: |
General
Partner | |||
By: |
/s/ Xxxxxxx
Xxxxxxxxx | |||
| ||||
Name: |
Administrative Partner of
HealthCare
Partners V,
L.P. | |||
Title: |
The General Partner of
HealthCare | |||
Ventures V,
L.P. |
(additional signature pages follow)
Diversa
Stockholders (continued)
HEALTHCARE VENTURES VI,
L.P. | ||||
By: |
||||
Its: |
General
Partner | |||
By: |
/s/ Xxxxxxx
Xxxxxxxxx | |||
| ||||
Name: |
Xxxxxxx
Xxxxxxxxx | |||
Title: |
Administrative Partner of
HealthCare
Partners VI,
L.P. | |||
The General Partner of
HealthCare
Ventures VI,
L.P. |
RHO MANAGEMENT TRUST
II | ||||
By: |
Rho Capital
Partners, Inc. | |||
Its: |
Investment
Advisor | |||
By: |
/s/ Xxxxxx
Xxxx | |||
| ||||
Name: |
Xxxxxx Xxxx | |||
Title: |
CEO |
RHO MANAGEMENT PARTNERS
L.P. | ||||
By: |
Atlas Capital
Corp. | |||
Its: |
General
Partner | |||
By: |
/s/ Xxxxxx
Xxxx | |||
| ||||
Name: |
Xxxxxx Xxxx | |||
Title: |
President |
(additional signature page follows)
Diversa
Stockholders (continued)
/s/ Xxx X. Short
|
Xxx X. Short, Ph.D.
|
/s/
Xxxxxx X. Xxxxx
|
Xxxxxx X. Xxxxx, Ph.D.
|
/s/ Xxxxxx X. Xxxxxxxx
|
Xxxxxx X. Xxxxxxxx
|
/s/ Xxxxx X. Xxxxxxxxx
|
Xxxxx X. Xxxxxxxxx, Ph.D. |
/s/ Xxxxx Xxxxxxx
|
Xxxxx Xxxxxxx
|
/s/ Xxxxxxx X. Xxxx
|
Xxxxxxx X. Xxxx
|
/s/ Xxxxx Xxxxxxx
|
Xxxxx Xxxxxxx
|
/s/ R. Xxxxxxx Xxxxx
|
R. Xxxxxxx Xxxxx
|
/s/ Xxxxxxx X.
Xxxxxxxx
|
R. Xxxxxxx X.
Xxxxxxxx
|
Exhibit A
Subject
Shares
Stockholder
|
Class of Stock
|
Number of Shares Owned
| ||
HealthCare Ventures III,
L.P. |
Common
Stock |
3,231,679 | ||
HealthCare Ventures IV,
L.P. |
Common
Stock |
949,929 | ||
HealthCare Ventures V,
L.P. |
Common
Stock |
1,677,658 | ||
HealthCare Ventures VI,
L.P. |
Common
Stock |
638,500 | ||
Rho Management Trust
II |
Common
Stock |
1,634,230 | ||
Rho Management Partners
L.P. |
Common
Stock |
47,931 | ||
Xxx X. Short,
Ph.D. |
Common
Stock |
415,670 | ||
Xxxxxx X. Xxxxx,
Ph.D. |
Common
Stock |
259,513 | ||
Xxxxxx X.
Xxxxxxxx |
Common
Stock |
650,632 | ||
Xxxxx X. Xxxxxxxxx,
Ph.D. |
Common
Stock |
10,000 | ||
Xxxxx Xxxxxxx |
Common
Stock |
5,000 | ||
Xxxxxxx X.
Xxxx |
Common
Stock |
158,536 | ||
Xxxxx Xxxxxxx |
Common
Stock |
46,539 | ||
R. Xxxxxxx
Xxxxx |
Common
Stock |
79,719 | ||
Xxxxxxx X.
Xxxxxxxx |
Common
Stock |
1,151 |